Conflicts of interest have kept Lars Rebien Sørensen away from pharmaceutical boards – until now

Up until now, Lars Rebien Sørensen has refrained from taking on board roles at pharmaceutical companies due to the risk of conflicts of interest. Now, the chairman of the Novo Nordisk Foundation will be taking on the role of chairman of the board at Ferring, although he highlights one possible conflict of interest with Denmark's largest pharmaceutical giant.

Lars Rebien Sørensen, chairman of the board of directors at Novo Nordisk Fonden and Ferring Pharmaceuticals

As the future chairman of Ferring Pharmaceuticals, Lars Rebien Sørensen will soon be taking on his first board role within the pharmaceutical industry.

Although he is a high profile figure in the Danish pharmaceutical industry, and in spite of his many years as the top executive at Novo Nordisk and his current role as the chairman of the Novo Nordisk Foundation, he has never before sat on the board of a pharmaceutical company.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs